Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. (20th August 2019)

• Record Type: Journal Article
• Authors: Corrie, P G; Marshall, A; Nathan, P D; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, C G; Marples, M; Danson, S J; Marshall, E; Houston, S J; Board, R E; Waterston, A M; Nobes, J P; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Patel, P M; Ottensmeier, C H; Farrugia, D; Humphreys, A; Eccles, B; Young, G; Barker, E O; Harman, C; Weiss, M; Myers, K A; Chhabra, A; Rodwell, S H; Dunn, J A; Middleton, M R;
• Is Part Of: Annals of oncology. Volume 30:Number 12(2019)
• Page Start: 2013
• Page End: 2014
• Publication Date: 2019-08-20
• Subjects: Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdz237
• Languages: English
• ISSNs: 0923-7534